董事名單與其角色和職能 自二零二四年十二月十七日起，聯康生物科技集團有限公司董事會（「董事會」）成 員載列如下： 執行董事 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* 梁國龍先生 （ 主席 ） 陳大偉先生 （ 副主席 ） 趙志剛先生 （ 行政總裁 ） 聞亞磊博士 （於開曼群島註冊成立之有限公司） （股份代號：0690） 非執行董事 邱國榮先生 張清女士 周啓明先生 任啓民先生 馬青山先生 以下提供各董事會成員於各董事委員會中所擔任職位的資料： 審核委員會 周啓明先生 （ 審核委員會主席 ） 任啓民先生 馬青山先生 薪酬委員會 周啓明先生 （ 薪酬委員會主席 ） 梁國龍先生 任啓民先生 馬青山先生 提名委員會 梁國龍先生 （ 提名委員會主席 ） 周啓明先生 任啓民先生 馬青山先生 香港，二零二四年十二月十七日 * 僅供識別 獨立非執行董事 ...

（於開曼群島註冊成立之有限公司） （股份代號：0690） UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* 委任執行董事 及首席營運官 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公佈全部或任 何部分內容而產生或因倚賴這些內容引起的任何損失承擔任何責任。 – 1 – 專業成就 貢獻與影響： . 聞亞磊博士的卓越領導和專業貢獻，不僅豐富了集團的產品線，也為集團的 營收增長和市場擴張做出了不可磨滅的貢獻。他的工作不僅推動了科研成果 的商業化，也為行業的技術進步和創新發展樹立了典範。 董事會宣佈，下列事項自二零二四年十二月十七日起開始生效： 聞亞磊博士（「聞博士」）已獲委任為執行董事及首席營運官。 聞博士之履歷詳情載列如下： 聞博士，60歲，獲得華南理工大學化學工程博士學位。 職業經歷： . 聯 康 集 團 ： 作 為 集 團 元 老 級 高 管 ， 聞 亞 磊 博 士 在 化 學 藥 品 和 生 物 產 品 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 重組膠原蛋白二類醫療器械獲批 肌顏態®醫療美容產品上市 二零二四年十二月二日 — 聯康生物科技集團有限公司（「本公司」），連同其附屬 公司統稱（「本集團」）董事會（「董事會」）欣然宣佈兩項重要里程碑，展示了本集團 在醫療美容和皮膚解決方案領域的持續增長和創新。 本 集 團 與 重 慶 民 濟 醫 療 器 械 有 限 公 司 的 戰 略 合 作 產 品 — 醫 用 重 組 膠 原 蛋 白 敷 料，已成功獲批二類醫療器械註冊證，註冊證編號為「渝械注准20242140377」。與 此同時，本集團自主研發的纖連蛋白醫療美容產品 — 肌顏態®也正式上市。這些 成就凸顯了聯康 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任 何部分內容或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 關連交易 — 貸款更替 於二零二四年十一月二十九日，貸款人（ 本公司之間接全資附屬公司 ）、原借款 人及新借款人訂立貸款更替協議，據此，新借款人同意承擔原借款人對貸款人 所欠本金額為人民幣8,500,000元的已更替貸款。新借款人為原借款人的控股公 司。 貸款更替並不構成上市規則第14章項下本公司的須予披露交易，但就上市規則 第14A章而言，構成本公司的關連交易。 由於有關作出貸款更替的最高適用百分比率（ 定義見上市規則 ）超過0.1 %但低於 5 %，故貸款更替須遵守公佈及申報規定，但豁免遵守上市規則第14A章項下的 通函及獨立股東批准規定。 引言 茲提述本公司日期為二零二三年九月 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 聯康生物科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期： 2024年11月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任 何部分內容而產生或因倚賴這些內容引起的任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 委任非執行董事及授出購股權 — 附加資料 茲提述聯康生物科技集團有限公司（「本公司」）日期為二零二四年十一月一日的公 告（「該公告」），內容有關委任張清女士（「張女士」）為本公司非執行董事及向張女 士授出購股權。除另有界定者外，本公告所用詞彙與該公告所界定者具有相同涵 義。 誠如該公告所載，購股權的歸屬及行使不受任何表現目標所約束，乃由於授出購 股權的目的為作為張女士獲委任為董事的薪酬的一部分。 購股權計劃的目的是為合資格人士就其對本集團的貢獻或潛在貢獻提供激勵或獎 勵。董事會薪酬委員會認為，考慮到(i)提呈購股權作為股權薪酬將為張女士薪酬 組合的一部分，可導致有限支付現金薪酬， ...

UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 董事名單與其角色和職能 自二零二四年十一月一日起，聯康生物科技集團有限公司董事會（「董事會」）成員 載列如下： 獨立非執行董事 周啓明先生 任啓民先生 馬青山先生 以下提供各董事會成員於各董事委員會中所擔任職位的資料： 審核委員會 周啓明先生 （ 審核委員會主席 ） 任啓民先生 馬青山先生 薪酬委員會 周啓明先生 （ 薪酬委員會主席 ） 梁國龍先生 任啓民先生 馬青山先生 執行董事 梁國龍先生 （ 主席 ） 陳大偉先生 （ 副主席 ） 趙志剛先生 （ 行政總裁 ） 非執行董事 邱國榮先生 張清女士 提名委員會 梁國龍先生 （ 提名委員會主席 ） 周啓明先生 任啓民先生 馬青山先生 香港，二零二四年十一月一日 * 僅供識別 ...

聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 委任非執行董事及授出購股權 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任 何部分內容而產生或因倚賴這些內容引起的任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 張女士所擁有的深厚醫藥行業背景及豐富的新藥投資和技術投資經驗，會為本公 司董事會在研發方面的決策提供更多的意見與支持。同時，張女士在美國的工作 履歷和資源，會為本公司拓展海外業務與國際化發展提供幫助。 除上文所披露者外，於本公告日期，張女士與本公司任何董事、高級管理層、主 要股東或控股股東（ 具有上市規則所賦予之涵義 ）概無任何關係。除上文所披露者 * 僅供識別 – 1 – 董事會宣佈，下列事項自二零二四年十一月一日起開始生效： 張清女士（「張女士」）已獲委任為非執行董事。 張女士之履歷詳情載列如下： 張清女士，37歲，自二零二零年至今擔任一家美國股權 ...

Financial Performance - Revenue for the six months ended June 30, 2024, reached approximately HKD 273.6 million, representing a year-on-year increase of 9.5% compared to HKD 249.9 million in 2023[4] - Gross profit for the same period was HKD 230.6 million, with a gross margin of 84.3%, up from 79.6% in the previous year[4] - Profit before tax surged by 64.9% to HKD 71.5 million, compared to HKD 43.4 million in the prior year[5] - The company achieved a significant operating profit of HKD 87.2 million, a 59.2% increase from HKD 54.7 million in the previous year[5] - The company recorded a record profit of approximately HKD 67.4 million, a significant year-on-year increase of 71.0%, with earnings per share reaching approximately HKD 1.09, reflecting a strong growth of 75.8%[32] - The total comprehensive income for the period was HKD 65,312,000, compared to HKD 30,013,000 in the prior year, reflecting a significant increase of 117.7%[71] - The net profit surged to approximately HKD 67.4 million, a remarkable increase of 71.0% from HKD 39.4 million in the first half of 2023[48] - The company reported a basic and diluted earnings per share of HKD 1.09 for the six months ended June 30, 2024, compared to HKD 0.62 in the same period of 2023, marking a 75.8% increase[71] Product Development and Launches - The company launched its fifth product, 博固泰*, in March 2024, contributing significantly to revenue growth[8] - The launch of Bogu Tai marks a new era in osteoporosis treatment, with sales expected to start in the first half of 2024 and a patient repurchase rate exceeding 65%[9] - The application for the launch of Diquafosol Sodium Eye Drops has been accepted, addressing the high demand in China's ophthalmic drug market, which has over 360 million dry eye patients[11] - The company is preparing for the fourth clinical study and real-world research of Bogu Tai, focusing on fracture prevention and pain relief, and plans to apply for FDA approval[10] - The company is focused on R&D in endocrinology, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[12] - The second-generation Uni-PTH (Bogu Tai) is the first pre-filled injection pen in China, designed for high dosing accuracy and minimal injection pain, officially approved in January 2024[15] - The third-generation oral Uni-PTH is currently in data collection for preparation, while the microneedle version is under development[15] Market Trends and Opportunities - The biopharmaceutical industry in China saw the approval of 44 new drugs in 2024, including 23 innovative drugs, reflecting a favorable regulatory environment[6] - The medical aesthetics market in China is projected to grow from RMB 200 billion in 2023 to RMB 288 billion in 2024, driven by consumer demand and technological advancements[6] - The dry eye drug market is projected to exceed RMB 42 billion by 2030, with a compound annual growth rate of 28.4%[11] - The biopharmaceutical market in China is projected to grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, driven by technological advancements and an aging population[49] - The medical aesthetics market is expected to maintain a CAGR of 10% to 15% from 2024 to 2027, reflecting increasing consumer spending on beauty standards[49] Research and Development - Research and development expenses increased to HKD 23.3 million, accounting for 8.5% of revenue, down from 9.2% in the previous year[4] - The company has initiated multiple R&D projects, including epidermal growth factor hydrogel wound dressings and is continuing to focus on endocrine diseases, ophthalmology, and dermatology[45] - The company is committed to investing in specialized peptide formulation technologies, despite potential increases in R&D expenses, as these investments are deemed crucial for long-term value creation[52] - The company incurred research and development expenses of HKD 20,890,000 for the six months ended June 30, 2024, compared to HKD 11,740,000 in the same period of 2023, which is an increase of 78.1%[70] Financial Stability and Liquidity - The debt-to-equity ratio improved to 55.8%, down from 59.4% in the previous year, indicating better financial stability[4] - Cash ratio improved to 1.30 times, up from 1.13 times in the previous year, indicating enhanced liquidity[4] - As of June 30, 2024, the company's cash and bank deposits amounted to approximately HKD 153.96 million, with total assets of approximately HKD 487.09 million, reflecting an increase from HKD 409.99 million as of December 31, 2023[57] - The company has a debt-to-total-assets ratio of 35.8% as of June 30, 2024, a decrease from 37.3% as of December 31, 2023, indicating improved financial stability[57] Strategic Initiatives - The company has organized nearly 400 academic conferences and activities to promote osteoporosis prevention and treatment, benefiting over 1,000 patients through public welfare initiatives[9] - The company is establishing a specialized sales team to promote its products and expand its market presence in the medical aesthetics sector, aiming for annual revenue exceeding RMB 30 million from this division within the next 2 to 3 years[51] - The company has entered a strategic partnership with Chongqing Minji Medical Devices Co., Ltd. to expand into the medical beauty device market, gaining exclusive distribution rights for complementary products[55] - The company has established an official flagship store on JD.com and partnered with over 200 online distributors to expand its online presence, enhancing market coverage and sales efficiency[53] Shareholder Information - The company repurchased a total of 201,180,000 shares during the six months ended June 30, 2024, including 115,180,000 shares in the first half of the fiscal year[64] - The number of shares issued and fully paid decreased to 6,163,588,147 shares as of June 30, 2024, from 6,364,768,147 shares as of December 31, 2023, a decrease of 3.2%[173] - As of June 30, 2024, the largest shareholder, Automatic Result Limited, holds 1,650,971,464 shares, representing 26.40% of the total issued shares[184] Operational Highlights - The company has made significant progress in the construction of a new factory in Dongguan, Guangdong, which includes a 4,300 square feet GMP standard production building and two 1,300 square feet GMP standard warehouses, aiming to produce 19 million units annually with a projected annual revenue exceeding RMB 1 billion[54] - The company established a new production facility in Dongguan, enhancing the production capacity of the eye drop product, Diquafosol Sodium, which is expected to be approved for market launch in Q1 2025[30] - The company plans to complete BFS packaging research and filing by 2025, with the launch of BFS packaged products expected in 2026, enhancing product safety and convenience[54] Miscellaneous - The company did not declare any interim dividend for the six months ended June 30, 2024[66] - The company has not reported any significant impact on its financial position or performance due to the adoption of new accounting standards[87] - The interim report has been reviewed by the company's audit committee[194] - The interim report is published on the Hong Kong Stock Exchange and the company's website[194]

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of approximately HKD 273.6 million, representing a year-on-year increase of 9.5%[2] - The company's profit reached approximately HKD 67.4 million, a significant year-on-year increase of 71.0%[1] - The group achieved a revenue growth of 9.5% year-on-year, reaching approximately HKD 273.6 million in the first half of 2024[6] - The net profit surged by 71.0% year-on-year, amounting to approximately HKD 67.4 million during the same period[6] - The flagship product 金因肽® generated revenue of approximately HKD 91.3 million, a decrease of 4.8% due to stricter procurement strategies in public hospitals[28] - The chemical drug, Pinanop®, saw revenue growth of 12.8%, increasing from approximately HKD 124.8 million to approximately HKD 140.9 million, attributed to successful re-selection for centralized procurement[30] - The newly launched product, Bogu Tai®, achieved sales of HKD 18.8 million within four months of its release, exceeding initial expectations[32] - The group recorded revenue of approximately HKD 273.6 million, representing a year-on-year growth of 9.5%[34] - Gross profit increased to approximately HKD 230.6 million, up 16.0% from HKD 198.9 million in the same period last year, with a gross margin of 84.3%, an increase of 4.7 percentage points[37] - Operating profit for the six months ending June 30, 2024, was HKD 71.808 million, up 63.8% from HKD 43.822 million in the prior year[60] - The total comprehensive income for the period was HKD 65.312 million, compared to HKD 30.013 million in the prior year[60] Product Development and Launches - Sales from the PinaPro® product line increased by 12.8% year-on-year, driven by successful procurement renewals from hospitals[1] - The company launched the BoguTai® product in March 2024, generating sales of HKD 18.8 million within four months[1] - The company is set to officially launch its first premium skincare product, Skbrella™ FN, expected to contribute to sales in the second half of 2024[1] - The company received approval for the market listing of sodium hyaluronate eye drops in January 2024, marking significant progress in its ophthalmic product portfolio[1] - The application for the approval of sodium diquafosol eye drops was accepted in January 2024, addressing the high demand in the Chinese ophthalmic market[9] - Diquafosol sodium eye drops are expected to be approved for market launch in Q1 2025, complementing the company's strong ophthalmic product portfolio[25] - The company is developing a third-generation oral Uni-PTH and a microneedle version, with data collection currently underway[13] - The company is developing UB105, a new oral hypoglycemic agent that combines GLP-1/GIP/GCG receptor agonists for effective weight loss and improved glycemic control[16] - The company has launched new skincare ingredients, including collagen and beauty peptides, enhancing its product line in the skincare market[18] - The company is developing new skincare ingredients including collagen, beauty peptides, microbiome skincare products, and exosome products, leveraging research ecosystems and rich experience in the cosmetics field[19] Research and Development - Research and development expenses amounted to HKD 23.3 million, representing 8.5% of revenue, down from 9.2% in the previous year[2] - The group is committed to R&D in endocrinology, ophthalmology, and dermatology, with multiple patented biopharmaceuticals in various stages of development[10] - R&D expenses for the first half of 2024 were approximately HKD 20.9 million, a 77.9% increase compared to approximately HKD 11.7 million in the same period of 2023[39] - The company is focused on technological innovation and expanding its influence in the biopharmaceutical and high-end medical device sectors[50] - Advanced synthetic biology and hydrogel technology platforms are being utilized to enhance product development and drug delivery systems[46] Market Trends and Opportunities - The biopharmaceutical industry in China saw the approval of 44 new drugs in 2024, including 23 innovative drugs, indicating a favorable environment for the company's growth[4] - The dry eye medication market is projected to exceed RMB 42 billion by 2030, with a compound annual growth rate of 28.4%[9] - The pharmaceutical sector in China is expected to grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, driven by technological advancements and an aging population[43] - The medical beauty market is projected to maintain a CAGR of 10% to 15% from 2024 to 2027, fueled by increasing consumer spending on beauty standards[43] - The company is exploring opportunities in the medical beauty sector, anticipating annual revenue exceeding RMB 30 million from this division within the next 2 to 3 years[45] Financial Position and Assets - As of June 30, 2024, the company's cash and bank deposits amounted to approximately HKD 153,964,000, with total assets of about HKD 487,086,000[51] - The company's current liabilities as of June 30, 2024, were HKD 118,316,000, with a debt-to-asset ratio of 35.8%[51] - The company's net assets increased to HKD 312,653,000 in June 2024, up from HKD 257,174,000 in December 2023, indicating a growth of 21.6%[62] - The company reported a net cash used in investing activities of HKD (35,800,000) for the six months ended June 30, 2024, compared to HKD (19,721,000) in the same period of 2023, representing an increase in cash outflow of 81.5%[63] - The company’s bank borrowings increased significantly to HKD 32,870,000 in June 2024 from HKD 11,035,000 in December 2023, a rise of 197.5%[61] Employee and Operational Efficiency - The company employed a total of 458 staff, including 32 in R&D and 216 in production in China[54] - Employee costs, including director remuneration, rose to HKD 64,281,000 for the six months ended June 30, 2024, compared to HKD 48,386,000 in the same period of 2023, reflecting an increase of about 33%[76] - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive growth[92] Stock Options and Shareholder Returns - The company has a total of 563,055,000 shares outstanding with a weighted average exercise price of HKD 0.18[95] - The company has a new stock option plan effective for ten years, allowing the board to grant options to eligible participants[92] - The company has not exercised any stock options during the reporting period[94] - The company aims to maintain its ability to continue as a going concern and provide returns to shareholders while supporting stability and development[98]